Semaglutide Injection (Wegovy®) for Chronic Weight Management in Adult Patients with Established Cardiovascular Disease
Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for semaglutide injection (Wegovy) as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of equal to or greater than 27 kg/m2 and established cardiovascular (CV) disease (heart attack, stroke, or peripheral arterial disease).